Biotech | March 25, 2026
Earendil Labs bags $787m to supercharge AI-driven biologics pipeline
Capital infusion to accelerate Earendil’s R&D platform
Capital infusion to accelerate Earendil’s R&D platform
Backed by Semaglutide launches, the company reported 47% quarter-on-quarter revenue growth in Q4 FY26, with EBITDA expanding more than fivefold
Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA
Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
Subscribe To Our Newsletter & Stay Updated
